ESMO 2024 – Incyte tries again in anal cancer
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.